Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

HomeAll NewsMost read newsBusiness Leaders Biography 
Portrait de Michel Vounatsos
Age : 59
Public asset : 19,727,890 USD
Country of residence : Unknown
Linked companies : PerkinElmer, Inc.

Biography of Michel Vounatsos 
Michel Vounatsos is on the board of PerkinElmer, Inc. (United States), L’Institut de RYthmologie et Modélisation Cardiaque and n-Lorem Foundation and Chief Executive Officer & Director at Biogen, Inc. In his past career he occupied the position of President-Primary Care & Customer Business Line at Merck & Co., Inc. Mr. Vounatsos received an MBA from École des Hautes Études Commerciales de Paris.


Current positions of Michel Vounatsos 
Holdings of Michel Vounatsos 
Michel Vounatsos : Personal Network 
Most Read News 
11/20Buffett's Berkshire boosts stakes in Japan's five biggest trading houses
RE
11/23Berkshire Hathaway says Warren Buffett donates shares to family charities
RE
12/01Salesforce shares tumble after surprise exit of co-CEO Taylor
RE
11/30Meta's Zuckerberg says some of Elon Musk's Twitter content approach 'might work'
RE
11/30Juventus has no requirement of additional capital, says Exor's Elkann
RE
11/30Interpol confirms red notice for Angolan billionaire Isabel dos Santos
RE
11/18Musk's pay trial asks if Tesla's growth justifies $56 billion compensation
RE
11/22'Boomerang CEOs' don't always work out; Disney hopes this one bucks trend
RE
11/21Musk says Twitter to hold off relaunching blue check verification
RE
11/19Musk's Twitter poll showing narrow majority want Trump reinstated
RE
More news


© 2022 People and Ownership :   
Michel Vounatsos : Connections 


Latest news about Michel Vounatsos 
11/10Biogen Names Christopher Viehbacher CEO
MT
11/10Biogen hires former Sanofi head Viehbacher as CEO
RE
11/10Biogen names Christopher Viehbacher as CEO
RE
11/10Biogen Inc. Announces Board and Executive Changes
CI
11/10Biogen Inc. Announces Executive Changes
CI
10/25Transcript : Biogen Inc., Q3 2022 Earnings Call, Oct 25, 2022
CI
10/25Biogen confident in Alzheimer's drug ahead of rivals' data
RE
More news